misoprostol

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
Major congenital malformations2.86 [1.44, 5.65]0%3 studies36388not evaluable
All congenital malformations (majors, minors, majors and minors, or unspecified)2.64 [1.03, 6.76]-1 study86118not evaluable
Nervous system anomalies4.23 [1.47, 12.16]-1 study34145not evaluable
Limb reduction defects15.12 [5.53, 41.34]0%2 studies6147not evaluable
Moebius syndrome32.19 [10.54, 98.31]0%2 studies12574not evaluable
Oro-facial clefts5.74 [1.34, 24.59]-1 study3452not evaluable
Abdominal wall defects6.36 [2.38, 16.96]-1 study3423not evaluable
Vascular disruption anomalie22.00 [6.59, 73.42]-1 study9344not evaluable
5 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
preterm (< 37 weeks)3.51 [1.38, 8.91]-1 study20145not evaluable

Intrauterine deaths
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
Early intrauterine death (< 22 weeks)2.16 [1.40, 3.34]36%2 studies36296not evaluable
Intrauterine deaths (as a whole)2.27 [1.30, 3.97]-1 study4694not evaluable
Elective termination of pregnancy5.33 [2.93, 9.71]-1 study74236not evaluable
2 non statistically significant endpoints reported in only one study